Start Your Search
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
EP1.01-64 - Effect of Amrubicin in Patients with Previously Treated Non-Small-Cell Lung Cancer (Now Available) (ID 599)
08:00 - 18:00 | Presenting Author(s): Shin Takayama
Although the prognosis of non-small cell lung cancer (NSCLC) has been rapidly improved due to the appearance of various tyrosine kinase inhibitors and immune checkpoint inhibitors, cytotoxic chemotherapy are still important treatment for patients who can’t receive these drugs or are ineffective for these drugs. Amrubicin (AMR) couldn’t significantly improve the progression free survival compared with docetaxel in a randomized phase III trial of Japanese previously treated NSCLC patients, but median progression free survival (PFS) and overall survival (OS)were comparable in the amrubicin and docetaxel groups. The purpose of this study is to clarify the use of amrubicin in clinical practice.Method
From January 2014 to March 2019, 479 progressive or recurrent NSCLC patients received chemotherapy or radiotherapy. Only 27 patients received AMR. We retrospectively evaluated these 27 patients.Result
None of the NSCLC patients who received AMR had epidermal growth factor recepter gene mutations nor anaplastic lymphoma kinase gene translocations. Median number of prior chemotherapy regimens was four, and median PFS was 62 days and OS was 229 days. Overall response rate was 7.4% and disease control rate was 37.0%.Conclusion
AMR was often used for patients considered to have a poor prognosis, and its effect was limited.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.